iqvia glp-1 prescriptions semaglutide tirzepatide q3 2024 Antagonists Increase Plan Drug Spend - What's Next Decoding the Buzz Around Weight-loss
Description
First-time prescribing of AOMs was about the same in December 2025, relative to September 2025 (-1.0%)
These observations underscore the importance of weight management strategies as a therapeutic consideration in patients with obesity and headache disorders
Gut metagenome in European women with normal, impaired and diabetic glucose control
What do you think this approval means for the future of obesity care
In its statement, the FDA said it is also taking steps to combat misleading direct-to-consumer advertising and marketing following warning letters that were sent in the fall of 2025.
